STOCKS TELEGRAPH

Author: Maria Masood

  • Kaival Brands Innovation Group, Inc. (KAVL) Stock Flying High in Early Trading, Here’s why.

    Kaival Brands Innovation Group, Inc. (KAVL) Stock Flying High in Early Trading, Here’s why.

    Kaival Brands Innovation Group, Inc. (KAVL) is engaged in the growth and incubation of novel products into established and leading businesses in the market. Kaval is the sole international supplier of product range manufactured by Bidi Vapor.

    The price of KAVL stock during the early trading hours on February 3, 2022, was $0.76 with a surge of 21.11%.

    KAVL: Events and Happenings

    On February 3, 2022, KAVL was updated about the grant of judicial stay to Bidi Vapor by the Court of Appeals for the Eleventh Circuit in lieu of the FDA-issued marketing denial order.

    KAVL: CEO Comments

    Speaking at the occasion, KAVL and Bidi Vapor CEO Niraj Patel stated that the company is expecting a rebounding of BIDI Stick sales after the judicial stay. He further added that BIDI Stick is apt for the protection of public health in view of the research performed.

    On January 31, 2022, KAVL was notified about the late submission of its annual report. On January 31, 2022, KAVL updated about the receipt of notification from Nasdaq regarding non-compliance of the least closing bid price requirement of $1.00 per share. The common stock of the company was less than $1.00 per share for 30 days consecutive trading period.

    On December 14, 2021, Bidi Vapor informed that most of the survey participants of e-cigarette smokers in the UK chose the BIDI Stick over other options. On December 6, 2021, KAVL reported on collaboration with Koupon for the creation of an E-engagement platform including Koupon’s online promotion program. The collaboration helped the BIDI Stick users in creating online opportunities based on their acquisitions.

    On October 6, 2021, KAVL updated about attending the 2021 NACS show held on October 5-8, 2021. On October 4, 2021, KAVL announced the closure of its underwritten public offering of 4,700,000 shares of common stock and warrants to acquire 3,525,000 shares. The public price of common stock shares was $1.70 per share. The company reported net proceeds of $8.0 million.

    Conclusion

    KAVL stock just hit n new low in the year. A sharp decline of 96% was observed over the yearly period as the company is economically struggling in a pandemic. The stock of the company escalated in Thursday’s early trading session as the company announced Bidi Vapors judicial stay win.

  • Here’s the Reason of Soaring Premarket Stock of Biocardia, Inc. (BCDA)

    Here’s the Reason of Soaring Premarket Stock of Biocardia, Inc. (BCDA)

    Biocardia, Inc. (BCDA) is a leading regenerative therapeutics firm engaged in the development of therapeutics for cardiovascular diseases. The lead pipeline candidate of the company is CardiAMP used in treating heart attack and chronic myocardial ischemia. Bone marrow-derived mesenchymal stem cell therapy is another lead candidate for its therapeutic potential against ischemic systolic myocardial infractions.

    The price of BCDA stock during the regular trading on February 2, 2022, was $1.57 with a dip of 6.55%. At last check in the premarket on February 3, 2022, the stock price rocketed by 27.3%.

    Events and Happenings

    On February 3, 2022, BCDA updated about the grant of Breakthrough Device Designation by the FDA to the lead candidate CardiAMP Cell Therapy System. It is considered to be the pioneer receiver of cardiac cell therapy by FDA.

    BCDA: CEO Comments

    Speaking at the momentous occasion, BCDA CEO Peter Altman stated that the previously published results of the clinical studies had met the company’s expectations. He further added that the company had added three elements to enhance its success probability after certain discrepancies in the previous trials.

    On January 10, 2022, BCDA reported that the Executive management participated at the following virtual investor conferences.

    • The H.C. Wainwright BioConnect Virtual Conference on January 10-13
    • The Biotech Showcase taking place January 10-12

    On December 15, 2021, BCDA updated about its entry into a long-term contract for a new building location. The facility provides growth opportunities to the production of the company’s product candidates.

    BCDA: Key Financials

    On November 10, 2021, BCDA released its financial results for the third quarter of 2021. Some of the important updates are as follows

    Revenue

    Revenue recorded in Q3 2021 was $0.82 million compared to $0.03 million in the same period of 2020. The analyst’s estimate of the revenue for the quarter was $0.04 million.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $2.7 million or $0.16 compared to $3.8 million or $0.30 per share in the same quarter of 2020. The company topped the analysts’ consensus estimates of $0.21 net loss by $0.05.

    Conclusion

    BCDA stock downplayed by 55% from the past few months as the companies are showing decelerating trend due to pandemics. The company’s recent premarket leap came after the FDA’s approval of breakthrough device designation by CardiAMP. The company’s stock is outperforming and is capable to attract investments.

  • Here’s why SOC Telemed, Inc. (TLMD) Stock Rocketing Higher in Premarket

    SOC Telemed, Inc. (TLMD) is a key provider of critical telemedicine solutions to the health care systems and physician networks. The company’s tech portfolio Telemed IQ deploys and optimizes the programs along the continuum of care. The company virtually delivers patient care in different sectors including neurology, psychiatry, pulmonology, cardiology, nephrology, and maternal-Fetal health care.

    The price of TLMD stock during the regular trading on February 2, 2022, was $0.64 with a decline of 9.28%. At last check in the premarket on February 3, 2022, the stock rocketed phenomenally by 336.6%.

    TLMD: Events and Happenings

    On February 3, 2022, TLMD announced its entry into a definitive contract of acquisition to be purchased by Patient Square Capital firm. The company’s shareholders will receive per share cash of $3.00 of its common stock. The acquisition price per share represented a hike of up to 366.1% over the company’s closing price of the share on the last full trading day prior to the announcement.

    TLMD: CEO Comments

    Speaking at the occasion, TLMD CEO Chris Gallagher stated that the notification of acquisition authenticates the company’s clinical services portfolio for critical care telemedicine. He further added that with the expert assistance and team support at Patient Square Capital, the company is well-positioned to meet the ever-increasing requirements of customers.

    TLMD: Key Financials

    On November 12, 2021, TLMD released its financial results for the third quarter ended September 30, 2021. Some of the key financial highlights are as follows.

    Revenue

    Total Revenue in Q3 2021 was $26.7 million compared to $15.1 million in the same period of 2020. Over the year, the total revenue increased by 76%. The company beat the estimated revenue by $1.41 million.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $10.6 million or $0.11 compared to $9.7 million or $0.34 in the same period of 2020. The company’s actual EPS beat the estimated EPS by $0.05.

    On September 16, 2021, TLMD and Ob Hospitalist Group co-reported their partnership merging the company’s maternal-fetal medicine expertise with the leading OB hospitalist programs. The primary hospital partner for this collaborative service provider is Hendrick Medical Center, Texas.

    Conclusion

    TLMD stock price is at its lowest six-months point. The company’s stock plummeted by 85% due to slow economic activities in the pandemic period. The tremendous gain in the premarket is the outcome of the company’s merger with a leading health care investment firm. The company’s earnings release date is also coming closer as the analysts estimate revenue of about $26.1 million.

  • Sundial Growers Inc. (SNDL) Stock Dipping in Premarket, Here’s What you Should Know.

    Sundial Growers Inc. (SNDL) is engaged in the production of small-batch cannabis utilizing the noveel indoor facilities. The company offers the finest customer experience and best quality cannabis products. The company operates under segments including Operations, Retail, and Investments.

    The price of SNDL stock during the regular trading on February 2, 2022, was $0.48 with a slight decline of 1.08%. At last check in the premarket on February 3, 2022, the stock further dipped by 4.41%.

    SNDL: Events and Happenings

    On January 24, 2022, SNDL updated about its allocation to BBB+ investment-grade ranking by Egan-Jones Ratings Company. On January 6, 2022, SNDL and Alcanna Inc. co-announced their agreement of progression of the cognition to be given to Alcanna’s stockholders for their common shares by the inclusion of a cash component.

    On December 8, 2021, SNDL reiterated its pledge to the plan of agreement with Alcanna. The stockholders of Alcanna will receive 10.69 SNDL’s common shares per common share of Alcanna. On December 2, 2021, SNDL’s JV Sunstream IVXX Investment Corp. reported about the submission of a draft registration statement privately to the SEC for a preliminary public offering of its common stock. The number and price of shares to be sold had not been determined. The net proceeds from the transaction will be used to invest in the debt of companies. The offering will be expected to commence in the first quarter of 2022.

    On November 11, 2021, SNDL updated about the approval of the share reacquisition program by BoDs. The program authorized to reacquire approximately C$100 million of the company’s outstanding common shares.

    SNDL: Key Financials

    On November 11, 2021, SNDL released its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Gross revenue in Q3 2021 was $11 million compared to $15.5 million in the same period of 2020. The company missed the estimated revenue by $1.39 million.

    Earnings

    Net earnings for Q3 2021 were $11.3 million compared to a net loss of $71.4 million in the same period of 2020. The company’s actual EPS was in-line with the estimated EPS.

    Conclusion

    SNDL had lost up to 40% over the past six months period due to down-falling economic conditions during a pandemic. The company’s stock also dipped in the recent aftermarket session due to uncertain factors as the company showed no recent activity. As the company is approaching its next earnings release date, the financial experts believe good turn out by the company.

  • Blend Labs, Inc. (BLND) Stock Nose-Diving in Pre-Market, Here’s the Reason

    Blend Labs, Inc. (BLND) is focused on the development of a cloud banking portfolio to drive the customer’s journey for any banking product. The company’s technology is utilized by financial services business providers for increased productivity and the acquisition of more clients.

    The price of BLND stock during the regular trading on February 2, 2022, was $8.52 with a slight decline of 0.58%. At last check in the pre-market, the stock further went down by 8.33%.

    BLND: Events and Happenings

    On February 2, 2022, BLND reported about the filing of statements of changes in the beneficial ownership. On January 4, 2022, BLND announced the participation of its Executive management Needham Growth Conference on January 10, 2022. On December 8, 2021, BLND reported about the adoption of Blend Close by approximately 125 lenders. Blend Close is the company’s online mortgage and home equity products closing solution.

    On December 3, 2021, BLND updated about its management’s participation at UBS Global TMT Conference on December 6, 2021. On November 22, 2021, BLND announced its Executive presentation at KBW Innovation in Finance Conference on December 7, 2021. On November 19, 2021, BLND announced its Executive’s participation at Wells Fargo TMT Summit on December 2, 2021.

    On November 17, 2021, the company announced the expansion of its ties with Paramount Residential Mortgage Group, Inc. Both the companies agreed to bring effective experiences to homeowner’s insurance, mortgage origination, closing, and income verification. On November 11, 2021, BLND updated about the participation of its management at the CITI FinTech Conference on November 18, 2021.

    BLND: Key Financials

    On November 10, 2021, BLND released its financial results for the third quarter ended September 30, 2021. Some of the key features are as follows.

    Revenue

    Total revenue in Q3 2021 was $89.5 million compared to $27.8 million in the same period of 2020. The company beat the estimated revenue by $3.35 million.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $76.3 million or $0.38 versus $15.2 million or $0.38 in the same period of 2020. The company missed the estimated EPS by $0.02.

    Conclusion

    BLND stock is down performing for the past six months period due to various reasons one being the pandemic-related slow economic activity. The company’s stock showed a declining trend in the pre-market session today as the company reported the recent SEC filing. The financial experts are attributing the declining trend to the recent SEC filings by the company.

  • Here’s why Matterport, Inc. (MTTR) Stock Dipped in Aftermarket

    Matterport, Inc. (MTTR) is an online global transformation company engaged in improving each and every part of the building lifecycle. The company’s innovative spatial figures portfolio turns buildings into data to transform them into more valued and accessed space.

    The price of MTTR stock during the regular trading on February 2, 2022, was $8.72 with a steep dip of 9.07%. At last check in the aftermarket, the stock was down by 7%.

    MTTR: Events and Happenings

    On February 02, 2022, MTTR announced the utilization of its Capture Services by Orangetheory to scan and produce online twins of its studios. On January 27, 2022, MTTR updated about enabling of cost and time-savings for a bunch of its retail customers by Retail VR. It utilizes MTTR’s Pro2 3D cameras and software development portfolios.

    On January 20, 2022, MTTR reported about the international expansion of its Capture Services to five more countries including Canada, France, Singapore Ireland, and the Netherlands.  On January 06, 2022, MTTR accomplished the purchase of Enview, Inc. The company acquired all of its issued and outstanding equity interests for the acquisition price of 1.59 million shares of its common stock.

    On December 16, 2021, MTTR reported on winning Best Company Culture and Best Company for Women awards. The company was ranked in the top 50 for small/medium-sized businesses in both groups.

    On December 09, 2021, MTTR updated about its adoption to accelerate the immediate redesign and renovation of RPM Pizza stores. On November 04, 2021, MTTR management participated in the following investor conferences.

    • Berenberg US CEO Conference on November 9.
    • P. Morgan Digital Twin Seminar on November 10.
    • Credit Suisse 25th Annual Technology Conference on November 30, and
    • Wells Fargo 5th Annual TMT Summit on December 1, 2021.

    MTTR: Key Financials

    On November 03, 2021, MTTR released its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Total revenue in Q3 2021 was $27.7 million compared to $25 million in the same period of 2020. The company’s revenue incline by 10% over the period of the year. The company missed on the estimated revenue by $1.49 million.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $168 million or $0.86 versus net income of $0.9 million in the same period of 2020. The company beat the estimated EPS by $0.02 per share.

    Conclusion

    MTTR performance dipped by 41% from the past six months due to the impact of the financial downturn as a result of the pandemic. The company’s stock again showed a declining trend in Wednesday’s aftermarket session after the announcement of the adoption of its digital twins by Orangetheory. The analysts are believing that the company should invest in advanced manufacture and marketing strategies of its products to elevate its overall position.

  • Syros Pharmaceuticals, Inc. (SYRS) Stock Rising in Aftermarket, Here’s why.

    Syros Pharmaceuticals, Inc. (SYRS) is a major developer of therapeutics for oncology and monogenic diseases. The company’s pipeline candidate includes tamibarotene tried for treating myelodysplastic syndrome and myeloid leukemia. Another lead candidate is SY-2101 is used in acute promyelocytic leukemia and SY-5609 in solid tumors.

    The price of SYRS stock during the regular trading on February 2, 2022, was $1.93 with a steep dip of 6.76%. At last check in the aftermarket, the stock was up by 7.25%.

    SYRS: Events and Happenings

    On February 2, 2022, SYRS announced the receipt of an orphan drug designation grant by FDA to its lead candidate tamibarotene. Clinical trials are underway for the treatment of the myelodysplastic syndrome. The Phase 3 SELECT-MDS-1 studies is assessing the efficacy and safety of tamibarotene along with azacitidine. The outcomes of the study are anticipated in Q4 2023 or Q1 2024.

    SYRS: CEO Comments

    On January 10, 2022, SYRS updated about its product’s clinical development portfolios. Speaking at the occasion, CEO of SYRS Nancy Simonian stated that in 2022, the company is looking forward to three clinical results readouts for its candidate products. She further added that the interactions regarding the company’s Phase 3 clinical study design of SY-2101 with the FDA were also optimistic.

    On November 16, 2021, SYRS’s Executive management participated in the following investor conferences.

    • Piper Sandler 33rd Annual Healthcare Conference on November 23.
    • JMP Securities Hematology and Oncology Summit on December 6, 2021.

    SYRS: Key Financials

    On November 5, 2021, SYRS released its financial results for the quarter ended September 30, 2021. Some of the highlights are as follows.

    Revenue

    Total Revenue recorded in Q3 2021 was $5.7 million compared to $3.8 million in the same quarter of 2020. The company beat the consensus-estimated revenue by $1.21 million.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $26.0 million or $0.41, compared to $19.5 million or $0.43 in the same period of 2020. The EPS beat by $0.03.

    On October 13, 2021, SYRS granted an award of inducement stock option to its CFO. The grant was accepted by the Board of Directors of the company.

    Conclusion

    SYRS stock downfall in the past few months due to financial limitations as a result of the pandemic. The company outperformed recently after its lead candidate was granted orphan drug designation by FDA. The company’s stock received a bullish rating from the financial analysts as it is gaining momentum in the market.

  • LogicBio Therapeutics, Inc. (LOGC) Stock Plummeting in Early Trading, Here’s why.

    LogicBio Therapeutics, Inc. (LOGC) is a leading gene therapy-focused company engaged in genome editing and gene delivery portfolios. The company’s pipeline has two genome editing portfolios to its badge, GeneRide, and sAAVy platforms to treat rare diseases of infants and adults.

    The price of LOGC stock during the regular early trading on February 2, 2022, was last checked to be $0.65 with a drop of 56.66%.

    LOGC: Events and Happenings

    On February 2, 2022, LOGC updated about its LB-001 clinical program which the FDA had put on hold. The company received a notification regarding its Phase 1/2 SUNRISE clinical studies of LB-001 in infants with methylmalonic acidemia disease.

    On January 4, 2022, LOGC’s Executive management presented at the H.C. Wainwright Bioconnect Conference held virtually on January 10-13, 2022.

    LOGC: Key Financials

    On November 15, 2021, LOGC released its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    The company missed the revenue target by $1.51 million. The total revenue recorded in Q3 2021 was $2.1 million, compared with $0.9 million for the same period of 2020. LOGC observed an increase of $1.2 million in revenue over the year.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $10.2 million or $0.31 compared to $8.0 million or $0.34 in the same quarter of 2020. The company missed the EPS target by $0.02 per share.

    On November 11, 2021, LOGC’s Executive management presented at the following two investor conferences.

    • Barclays Gene Editing & Gene Therapy Summit on November 15, 2021
    • Jefferies Virtual London Healthcare Conference on November 18, 2021.

    Conclusion

    LOGC dipped by 79% as the company down performed in the last half-year due to tight economic conditions. The company’s stock dipped in the current early trading due to the imposition of a clinical hold by the FDA on its lead product candidate. The analysts are believing this is a blow to the company’s clinical pipeline.

  • The OLB Group, Inc. (OLB) Stock Rallying in Early Trading, Here’s the Reason.

    The OLB Group, Inc. (OLB) is a leading digital Fintech services provider. The company is also involved in the Bitcoin crypto mining business. The digital portfolio of the company delivers cloud-based merchant facilities for a wide-ranging e-commerce solution. The crypto enterprise is focused on the mining of Bitcoin using sustainable natural gas.

    The price of OLB stock during the early regular trading on February 2, 2022, was last checked to be $2.35 with a 24.78% surge.

    OLB: Events and Happenings

    On February 2, 2022, OLB announced about touching $1.35 Billion in transaction volume by its merchant services annual transaction volume run rate as an outcome of 28.5 million transactions.

    OLB: CEO Comments

    Speaking at the occasion, Ronny Yakov, OLB’s CEO stated that 2021 began with an annualized revenue run rate of $10 million. He further added that 2022 started with an outstanding $36 million annualized revenue run rate which will contribute to the company’s bottom line.

    On January 13, 2022, a subsidiary of OLB reported about its expected to take delivery of the initial of four hundred Bitcoin mining machinery in January. The company is believed to generate $1 million in increased monthly revenue once all machinery is operational.

    On January 11, 2022, OLB announced its entry into a long-term lease partnership for its mining operation with an approximate capability of 2,000 machines. The area is under conversion process into a cryptocurrency mining data center.

    On December 1, 2021, OLB updated about its entry into a definitive partnership for the acquisition of cannabidiol merchants. The merchant platform had been anticipated to achieve a yearly transaction volume of up to $400 million during 2022. The company anticipated $5 million in earnings and $20 million yearly revenue.

    OLB: Key Financials

    On November 12, 2021, OLB released its financial results for the first quarter ended September 30, 2021. Some of the key highlights are as follows.

    Revenue

    For Q1 2022 the company recorded a revenue of $2.82 million compared to $2.3 million in the same period of 2020. The increase over the year in the revenue was $0.51 million or 22.3%.

    EPS

    Net loss in Q1 2022 was $0.9 million compared to $0.65 for the same period in 2020.

    Conclusion

    OLB stock down spiraled in the last six months period by 65% due to economic depression as a result of the pandemic. The current early trade leap in stock price is the result of achieving the yearly transaction volume run rate of $1.35 billion. The investors are optimistic that the company’s stock will climb further in the coming days.

  • Here’s why Dynatrace, Inc. (DT) Stock Sinking in the Premarket

    Dynatrace, Inc. (DT) is a software intelligence provider to simplify cloud complications and quicken online transformation. The company delivers automated observability at a faster pace along with the performance and security of applications to collaborate more effectively.

    The price of DT stock during the regular trading on February 1, 2022, was $56.2 with a 2.59% surge. At last check in the premarket on February 2, 2022, the stock went down by 17.57%.

    DT: Key Financials

    On February 2, 2022, DT announced its Q3 financial results for the fiscal year 2022 ended December 31, 2021. Some of the key updates are as follows.

    Revenue

    Total revenue in Q3 2022 was $240.7 million, compared to $170.3 million in the same quarter of 2021. The revenue increased by 32% over the year. The company’s revenue fell short of the estimated value.

    EPS

    Basic and diluted net income per share in Q3 2022 was $14.5 million or $0.05 compared to $18.4 million or $0.07 (basic) and $0.06 (diluted) for Q3 2021. The estimated EPS for the quarter was $0.16.

    DT: CEO Comments

    Speaking at the occasion, DT CEO Rick McConnell said that the company beat the high end of guidance across its key operating metrics and sustained a net expansion rate above 120%. He further added that the consumers view the company’s software intelligence portfolio as a vital portion of their online transformation ecosystem.

    DT: Events and Happenings

    On January 18, 2022, DT reported conclusions of an international survey regarding infrastructure management. The results of the survey revealed the trials faced by the administrations, as they want to attain agility and scalability, so they turn towards multi-cloud platforms.

    On November 30, 2021, DT announced the achievement of the Amazon Web Services Migration and Modernization Competency designation. This portfolio confirmed the company’s technical proficiency and proven success. On November 18, 2021, DT updated about the enhancement of its analytics capacities by merging its AI-based log monitoring with PurePath.

    On November 8, 2021, DT announced the inclusion of security gates in its portfolio thus allowing DevSecOps to evaluate and ensure the movement of secure code through the delivery pipeline.

    On November 4, 2021, DT announced the participation of its Executive management in two conferences. They include the Virtual RBC Capital Markets Technology, Internet, Media, and Telecommunications Conference on November 16 and Barclays Global Technology, Media and Telecommunications Conference on December 8, 2021.

    Conclusion

    DT stock down performed in the last six months period by 12% as the global economy slowed down in pandemic. The current dip in premarket stock is the result of its recently released quarterly report. The company’s EPS fell short of its estimated value, thus the financial experts are associating the declining stock with less EPS.